AzTrials
AzTrials

Substance Use DisordersIMPACTNCT04939012

Implementation of a Patient-centered, Reproductive Planning Decision Support Tool (MyPath) Among Women With Substance Use Disorder in the Immediate Postpartum Period

A study testing MyPath Intervention in people with Substance Use Disorders and Pregnancy Related, run by University of Pittsburgh at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This is a study to determine the effect of a novel patient-centered, reproductive planning decision support tool developed by the research team called MyPath on postpartum contraceptive decision-making among women with SUDs. Read more about this study

Who is it for?
Ages 18 years and older, women only
What is being tested?
MyPath Intervention
Could I receive a placebo?
No, everyone receives an active treatment
How many people
400 participants
Where
1 siteUnited States
Study dates
11 Oct 2022to 1 Mar 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Prenatal Cohort:
  • Be greater than or equal to 18 years of age.
  • Be pregnant with an EGA of 22 to 37 weeks at enrollment.
  • Plan to deliver at research site.
  • Meet DSM-5 criteria for a SUD (i.e., opioid, stimulant or other use disorder) and/or have a diagnosis code for a substance use disorder in their medical record.
  • Postpartum Cohort:
Show all 10Show fewer
  • Be greater than or equal to 18 years of age.
  • Be 0-9 days postpartum at enrollment.
  • Have delivered at research site.
  • Meet DSM-5 criteria for a SUD (i.e., opioid, stimulant or other use disorder) and/or have a diagnosis code for a substance use disorder in their medical record.

Who cannot join

  • Have had a fetal or neonatal death with their current pregnancy.
  • Be currently in jail or prison as required by court of law. Persons on probation or in residential facilities do not need to be excluded.
  • Have any other condition (social or medical) which, in the opinion of the Investigator, would make study participation unsafe, make study participation difficult, and/or complicate data interpretation.
  • PPC ONLY: Documented tubal ligation or hysterectomy procedures at time of delivery hospitalization

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Elizabeth Krans, MD contact

(412) 641-3532

kransee@upmc.edu

Samantha Mayo, BA contact

(412) 641-2248

mayos@upmc.edu

United States1 site, 1 recruiting
  • Magee Womens Hospital of UPMC

    Pittsburgh, Pennsylvania, 15213

    Mayo Samantha, BA, (412) 641-2248, mayos@upmc.edu

    Ellen Stewart, (412) 641-4984, stewartep@upmc.edu

    Recruiting

Other trials in United States

About this study

This is a study to determine the effect of a novel patient-centered, reproductive planning decision support tool developed by the research team called MyPath on postpartum contraceptive decision-making among women with SUDs.

Read the detailed description

The reproductive health needs of women with substance use disorders (SUDs) are unmet. Over 80% of pregnancies among women with SUDs are unintended, compared to 45% of the general population, and over 20% of women with SUDs have had a short interpregnancy interval (i.e. ≤ 18 months after a previous birth). Adverse reproductive health outcomes are perpetuated by contraceptive decisions that are inconsistent with women's reproductive goals. In an evaluation of women in opioid use disorder (OUD) treatment, only half of sexually active women not wanting to get pregnant used contraception, with condoms the most frequent method used. Pregnancy is a unique opportunity to address contraceptive needs due to increased healthcare access and expanded Medicaid eligibility, increased access to highly effective methods such as long-acting reversible contraception (LARC) and enhanced motivation to avoid rapid, repeat pregnancy. Despite this, over 75% of women with OUD do not use postpartum contraception and less than 2% receive LARC.

Currently, there are no effective strategies to improve postpartum contraceptive decision-making for women with SUDs. As an initial step to address this gap, the investigators conducted an observational study of postpartum contraceptive choices among 194 women with OUD at our maternity hospital (Plan NOW). Per usual care, women were provided with information about all contraceptive options, consistent with "information-based" counseling, and access to all methods including immediate postpartum LARC. Several findings informed this proposal. First, women's postpartum contraceptive decisions were often inconsistent with their childbearing goals. Among women who did not want another child, 36% did not choose a highly effective method and 10% had a repeat pregnancy within one year. Second, women had limited contraceptive knowledge and frequent misconceptions about their fertility and vulnerability to pregnancy. Third, women's decisional autonomy regarding sex and contraception was often threatened due to ongoing illicit drug use and reproductive coercion by partners. Fourth, women who wanted another baby did not feel supported and often felt pressured to choose a highly effective method. Therefore, failure to frame contraceptive decisions within the larger reproductive health context of women with OUD was a major barrier to high quality decision-making.

The goal of this research is to help women with SUDs make informed decisions about their reproductive health that align with their preferences, values and reproductive goals. Our objective in this application is to determine the effect of a novel patient-centered, reproductive planning decision support tool developed by the research team called MyPath on postpartum contraceptive decision-making among women with SUDs. Designed to facilitate high-quality decisions regarding pregnancy and contraception, MyPath helps women a) review their thoughts about pregnancy and children, b) learn about fertility and preconception health and c) prioritize their preferences for various contraceptive method characteristics (e.g. effectiveness, side effects). As such, MyPath uses a patient-centered approach to help women frame their contraceptive decisions in the context of their goals and health and is a critical first step towards addressing reproductive health inequities among women with SUDs. Our overarching hypothesis is that patient-centered, reproductive planning decision support will facilitate high quality decision-making and thus improve postpartum contraceptive utilization and reproductive health outcomes among women with SUDs. To test this hypothesis, the investigators propose a hybrid type 1 effectiveness-implementation randomized controlled trial, guided by the following aims:

Aim 1: Assess the effect of patient-centered, reproductive planning decision support (MyPath) on postpartum contraceptive utilization and reproductive health outcomes among women with SUDs

Aim 2: Determine if the relationship between MyPath and contraceptive utilization is mediated by decision quality. Decision quality will be measured using four patient-centered components of decision-making: knowledge, values concordance, decisional conflict and involvement. The investigators hypothesize that improvements in decision quality will mediate the relationship between MyPath and contraceptive utilization.

Aim 3: Identify barriers and facilitators to integrating MyPath into routine postpartum clinical care. The investigators will gather process evaluation data during the randomized controlled trial (RCT) and conduct qualitative interviews with key patient, provider and health system stakeholders to identify potential barriers and facilitators to future implementation in maternity settings and routine postpartum clinical care, if MyPath is found to be effective.

Being tested
MyPath Intervention, Usual care
Medical subject headings
Substance-Related Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MyPath InterventionBehavioural

    MyPath is a novel patient-centered, reproductive planning decision support tool developed by the research team used to facilitate postpartum contraceptive decision-making among women with SUDs. Designed to facilitate high-quality decisions regarding pregnancy and contraception, MyPath helps women a) review their thoughts about pregnancy and children, b) learn about fertility and preconception health and c) prioritize their preferences for various contraceptive method characteristics (e.g. effectiveness, side effects). As such, MyPath uses a patient-centered approach to help women frame their contraceptive decisions in the context of their goals and health and is a critical first step towards addressing reproductive health inequities among women with SUDs.

  • Usual careBehavioural

    Standard of Care

Study groups in NCT04939012
Study groupRoleWhat they receive
MyPath InterventionExperimentalAt the first visit participants randomized to this arm receive MyPath contraceptive decision tool.
Receives: Behavioral: MyPath Intervention
Standard of CareActive comparatorAt the first visit participants randomized to this arm receive standard of care contraceptive counseling.
Receives: Behavioral: Usual care

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Contraceptive method continuation

    Contraceptive method continuation as measured at each postpartum follow-up assessment by participants use of the same contraceptive method as she did at the previous timepoint.

    Measured: Delivery (Immediate Post-delivery Inpatient Visit) to 18 months post delivery

  2. Continuous contraceptive use

    Continuous contraceptive use as measured by participants continuously using any moderately (i.e., pill, patch, or ring, injection) or highly effective (i.e., long-acting reversible contraceptive (LARC), tubal ligation) method at consecutive timepoints. Reasons for stopping or switching methods will also be obtained.

    Measured: Delivery (Immediate Post-delivery Inpatient Visit) to 18 months post delivery

Secondary outcomes (7)
  1. Use of moderate or highly effective method

    Use of moderate or highly effective method as measured by participants who select any moderately (i.e., pill, patch, or ring, injection) or highly effective (i.e., long-acting reversible contraceptive (LARC), tubal ligation) method at any timepoint.

    Measured: Delivery (Immediate Post-delivery Inpatient Visit) to 18 months post delivery

  2. Unintended pregnancy

    Rate of unintentional pregnancy as measured by number of women having a new pregnancy, evaluation of intendedness of that pregnancy with the 6-item London Measure of Unplanned Pregnancy (LMUP).

    Measured: Delivery (Immediate Post-delivery Inpatient Visit) to 18 months post delivery

  3. Interpregnancy interval

    Time-to-next pregnancy as measured by time-to-event analyses.

    Measured: Delivery (Immediate Post-delivery Inpatient Visit) to 18 months post delivery

  4. Decisional Conflict

    Decisional conflict as measured by the Decision Conflict Scale (DCS).

    Measured: Enrollment (22 - 37 weeks pregnant) to 18 months post delivery

  5. Values concordance

    We will measure women's perceptions of the values concordance of their selected postpartum contraceptive method as measured by a two-item adapted Measure of the Alignment of Choices (MATCH)

    Measured: Enrollment (22 - 37 weeks pregnant) to 18 months post delivery

  6. Knowledge

    Reproductive planning knowledge as measured by an 18-item reproductive planning knowledge scale adapted from validated contraceptive knowledge assessments.

    Measured: Enrollment (22 - 37 weeks pregnant) to 18 months post delivery

  7. Involvement

    Involvement in decision making as measured by the Interpersonal Quality in Family Planning care (IQFP).

    Measured: Enrollment (22 - 37 weeks pregnant) to 18 months post delivery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Jun 2021
  2. Study start11 Oct 2022
  3. Primary completion1 Mar 2027 (estimated)
  4. Study completion1 Mar 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
400 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04939012
Sponsor's protocol ID
STUDY20110324
Other IDs
1R01DA051674-01A1
Acronym
IMPACT
Status last verified
Feb 2026
First submitted
23 Jun 2021
Last updated
17 Feb 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: The University of Pittsburgh study investigators will be responsible for publication of the results of this study. A publication plan according to the intellectual and scientific contribution of each member of the investigative team will be agreed upon prior to publication of study results.

Questions about this trial

What is this clinical trial studying?

A study testing MyPath Intervention in people with Substance Use Disorders and Pregnancy Related, run by University of Pittsburgh at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 17 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Elizabeth Krans, MD ((412) 641-3532, kransee@upmc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Contraceptive method continuation (time frame: Delivery (Immediate Post-delivery Inpatient Visit) to 18 months post delivery). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in